Mesalamine Oral Product ( DrugBank: Mesalamine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05488405 (ClinicalTrials.gov) | February 9, 2022 | 3/8/2022 | Mesalazine Oral Suspension in Active Eosinophilic Esophagitis | Open-label, Monocentric Phase IIa Pilot Study Evaluating the Efficacy and Tolerability of a 4-week Treatment With Mesalazine Oral Suspension in Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Mesalamine Oral Product | Dr. Falk Pharma GmbH | NULL | Recruiting | 18 Years | 75 Years | All | 10 | Phase 2 | Switzerland |